Published in J Natl Cancer Inst on October 16, 1996
Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst (2009) 7.95
REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer (2005) 4.85
The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer (2011) 3.45
Publication of tumor marker research results: the necessity for complete and transparent reporting. J Clin Oncol (2012) 2.05
BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received. Br J Cancer (2010) 1.99
Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review. Breast Cancer Res Treat (2011) 1.89
TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial. Lancet Oncol (2011) 1.85
Validation of novel imaging methodologies for use as cancer clinical trial end-points. Eur J Cancer (2008) 1.73
Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery. Oncologist (2010) 1.72
Radiomics: Images Are More than Pictures, They Are Data. Radiology (2015) 1.68
Validation of biomarker-based risk prediction models. Clin Cancer Res (2008) 1.57
Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis. Br J Cancer (2009) 1.53
Tumour-infiltrating inflammation and prognosis in colorectal cancer: systematic review and meta-analysis. Br J Cancer (2014) 1.51
A model citizen? Is tamoxifen more effective than aromatase inhibitors if we pick the right patients? J Natl Cancer Inst (2008) 1.45
Clinical analysis and interpretation of cancer genome data. J Clin Oncol (2013) 1.44
Tumoral TP53 and/or CDKN2A alterations are not reliable prognostic biomarkers in patients with localized Ewing sarcoma: a report from the Children's Oncology Group. Pediatr Blood Cancer (2014) 1.43
Breast cancer receptor status: do results from a centralized pathology laboratory agree with SEER registry reports? Cancer Epidemiol Biomarkers Prev (2009) 1.41
Biomarkers in Breast Cancer - An Update. Geburtshilfe Frauenheilkd (2012) 1.41
Human chitinases and chitinase-like proteins as indicators for inflammation and cancer. Biomark Insights (2007) 1.40
Comparative effectiveness research, genomics-enabled personalized medicine, and rapid learning health care: a common bond. J Clin Oncol (2012) 1.37
Molecular circuits of solid tumors: prognostic and predictive tools for bedside use. Nat Rev Clin Oncol (2010) 1.36
Circulating tumour cells and cell-free DNA as tools for managing breast cancer. Nat Rev Clin Oncol (2013) 1.33
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol (2016) 1.33
What should physicians look for in evaluating prognostic gene-expression signatures? Nat Rev Clin Oncol (2010) 1.29
Coprescription of tamoxifen and medications that inhibit CYP2D6. J Clin Oncol (2010) 1.21
Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update. Int J Cancer (2013) 1.21
Tumor infiltration by FcγRIII (CD16)+ myeloid cells is associated with improved survival in patients with colorectal carcinoma. Int J Cancer (2010) 1.16
Statistical consideration for clinical biomarker research in bladder cancer. Urol Oncol (2010) 1.12
Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol (2015) 1.11
A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer. JAMA Oncol (2017) 1.05
Prognostic significance of MET amplification and expression in gastric cancer: a systematic review with meta-analysis. PLoS One (2014) 1.03
Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy. Breast Cancer Res (2014) 1.03
C-Reactive Protein Is an Important Biomarker for Prognosis Tumor Recurrence and Treatment Response in Adult Solid Tumors: A Systematic Review. PLoS One (2015) 1.03
uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies. Breast Cancer Res (2014) 1.02
Mass spectrometry-based proteomics in molecular diagnostics: discovery of cancer biomarkers using tissue culture. Biomed Res Int (2013) 1.02
What is the clinical value of cancer stem cell markers in gliomas? Int J Clin Exp Pathol (2013) 1.02
Screening for colorectal cancer: possible improvements by risk assessment evaluation? Scand J Gastroenterol (2011) 0.99
Bridging the gap: moving predictive and prognostic assays from research to clinical use. Clin Cancer Res (2012) 0.99
Methodology and applications of disease biomarker identification in human serum. Biomark Insights (2007) 0.97
The diagnostics of colorectal cancer. Contemp Oncol (Pozn) (2013) 0.97
Overview of a chemoresponse assay in ovarian cancer. Clin Transl Oncol (2014) 0.96
Differential chemotherapeutic sensitivity for breast tumors with "BRCAness": a review. Oncologist (2013) 0.95
Beyond prostate-specific antigen: new serologic biomarkers for improved diagnosis and management of prostate cancer. Rev Urol (2004) 0.95
Detection of serological biomarkers by proximity extension assay for detection of colorectal neoplasias in symptomatic individuals. J Transl Med (2013) 0.94
FDG PET and tumour markers in the diagnosis of recurrent and metastatic breast cancer. Eur J Nucl Med Mol Imaging (2004) 0.93
Prognostic role of survivin in bladder cancer: a systematic review and meta-analysis. PLoS One (2013) 0.92
Quantitative measurement of cancer tissue biomarkers in the lab and in the clinic. Lab Invest (2014) 0.92
Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer: Updated Guidelines From the European Group on Tumor Markers. Int J Gynecol Cancer (2016) 0.91
Treatment Algorithms Based on Tumor Molecular Profiling: The Essence of Precision Medicine Trials. J Natl Cancer Inst (2015) 0.90
Serum tumor markers in pediatric osteosarcoma: a summary review. Clin Sarcoma Res (2012) 0.90
Biomarkers in Ewing Sarcoma: The Promise and Challenge of Personalized Medicine. A Report from the Children's Oncology Group. Front Oncol (2013) 0.90
Assessing value of innovative molecular diagnostic tests in the concept of predictive, preventive, and personalized medicine. EPMA J (2015) 0.89
Translating metastasis-related biomarkers to the clinic--progress and pitfalls. Nat Rev Clin Oncol (2013) 0.88
Long noncoding RNAs as novel predictors of survival in human cancer: a systematic review and meta-analysis. Mol Cancer (2016) 0.87
The prognostic significance of HOTAIR for predicting clinical outcome in patients with digestive system tumors. J Cancer Res Clin Oncol (2015) 0.87
Assessment of osteopontin in early breast cancer: correlative study in a randomised clinical trial. Breast Cancer Res (2014) 0.87
Future directions for monitoring treatment responses in breast cancer. J Cancer (2014) 0.87
Study designs and statistical analyses for biomarker research. Sensors (Basel) (2012) 0.86
Clinical Utility of a Plasma Protein Classifier for Indeterminate Lung Nodules. Lung (2015) 0.84
Comprehensive validation of published immunohistochemical prognostic biomarkers of prostate cancer -what has gone wrong? A blueprint for the way forward in biomarker studies. Br J Cancer (2014) 0.84
Prognostic and predictive value of thymidylate synthase expression in colon cancer. Dig Dis Sci (2007) 0.83
Incorporation of biomarker assessment in novel clinical trial designs: personalizing brain tumor treatments. Curr Oncol Rep (2011) 0.83
YKL-40-A Protein in the Field of Translational Medicine: A Role as a Biomarker in Cancer Patients? Cancers (Basel) (2010) 0.83
Predicting response to treatment in gastroesophageal junction adenocarcinomas: combining clinical, imaging, and molecular biomarkers. Oncologist (2010) 0.83
Growth factor receptors and apoptosis regulators: signaling pathways, prognosis, chemosensitivity and treatment outcomes of breast cancer. Breast Cancer (Auckl) (2009) 0.82
Assessment of Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1 in Breast Cancer Tissue: Historical Aspects and Future Prospects. Breast Care (Basel) (2008) 0.82
Transmembrane mucins as novel therapeutic targets. Expert Rev Endocrinol Metab (2011) 0.82
[Prognostic and predictive factors of invasive breast cancer: update 2009]. Pathologe (2009) 0.82
Circulating glioma biomarkers. Neuro Oncol (2014) 0.80
Prognostic relevance of ubiquitin C-terminal hydrolase L1 (UCH-L1) mRNA and protein expression in breast cancer patients. J Cancer Res Clin Oncol (2013) 0.80
Bone remodeling markers and bone metastases: From cancer research to clinical implications. Bonekey Rep (2015) 0.80
Contribution of biomarkers to personalized medicine. Breast Cancer Res (2010) 0.79
Expression of CA125 and cisplatin susceptibility of pleural effusion-derived human lung cancer cells from a Thai patient. Oncol Lett (2012) 0.79
OncoKB: A Precision Oncology Knowledge Base. JCO Precis Oncol (2017) 0.78
External validation of serum hCG cutoff levels for prediction of resistance to single-agent chemotherapy in patients with persistent trophoblastic disease. Br J Cancer (2009) 0.78
How close are we to customizing chemotherapy in early non-small cell lung cancer? Ther Adv Med Oncol (2011) 0.77
Tissue carcinoembryonic antigen and oestrogen receptor status in breast carcinoma: an immunohistochemical study of clinical outcome in a series of 252 patients with long-term follow-up. Br J Cancer (1998) 0.77
Experience in Phase I Trials and an Upcoming Phase II Study with uPA Inhibitors in Metastatic Breast Cancer. Breast Care (Basel) (2008) 0.77
A guide for clinicians in the evaluation of emerging molecular diagnostics for newly diagnosed prostate cancer. Rev Urol (2014) 0.77
Variation of tumoral marker after radiofrequency ablation of pancreatic adenocarcinoma. J Gastrointest Oncol (2016) 0.76
Biomolecular features of clinical relevance in breast cancer. Eur J Nucl Med Mol Imaging (2004) 0.76
The Evolving Role of Circulating Tumor Cells in the Personalized Management of Breast Cancer: from Enumeration to Molecular Characterization. Curr Breast Cancer Rep (2014) 0.76
HER2 and uPAR cooperativity contribute to metastatic phenotype of HER2-positive breast cancer. Oncoscience (2015) 0.76
Prospective Biomarker Trials Chemo N0 and NNBC-3 Europe Validate the Clinical Utility of Invasion Markers uPA and PAI-1 in Node-Negative Breast Cancer. Breast Care (Basel) (2008) 0.76
B-Raf mutation and papillary thyroid carcinoma patients. Oncol Lett (2016) 0.76
Biomarkers to Target Heterogeneous Breast Cancer Stem Cells. J Mol Biomark Diagn (2012) 0.75
Prognostic Impact of Epidermal Growth Factor Receptor Overexpression in Patients with Cervical Cancer: A Meta-Analysis. PLoS One (2016) 0.75
Prognostic significance of uPA/PAI-1 level, HER2 status, and traditional histologic factors for survival in node-negative breast cancer patients. Radiol Oncol (2016) 0.75
Association of osteopontin with specific prognostic factors and survival in adjuvant breast cancer trials of the Hellenic Cooperative Oncology Group. J Transl Med (2017) 0.75
The Challenges of Validating in Precision Medicine: The Case of Excision Repair Cross-Complement Group 1 Diagnostic Testing. Oncologist (2016) 0.75
Fluorouracil implants caused a diaphragmatic tumor to be misdiagnosed as liver metastasis: a case report. BMC Cancer (2016) 0.75
Assessment of the extent of unpublished studies in prognostic factor research: a systematic review of p53 immunohistochemistry in bladder cancer as an example. BMJ Open (2016) 0.75
The Pursuit of Noninvasive Diagnosis of Lung Cancer. Semin Respir Crit Care Med (2016) 0.75
Ultrasensitive Luminescent In Vitro Detection for Tumor Markers Based on Inorganic Lanthanide Nano-Bioprobes. Adv Sci (Weinh) (2016) 0.75
Recent advances in technologies for the detection of occult metastatic cells in bone marrow of breast cancer patients. Breast Cancer Res (2001) 0.75
Prognostic biomarkers in ovarian cancer. Cancer Biomark (2011) 0.75
Tumor marker utility grading system. J Natl Cancer Inst (1996) 0.75
Can biological markers improve the management of breast cancer patients? Biomarkers Ad-hoc Group of the United Kingdom Coordinating Committee on Cancer Research. Br J Cancer (2000) 0.75
Planning clinically relevant biomarker validation studies using the "number needed to treat" concept. J Transl Med (2016) 0.75
Selecting postoperative adjuvant systemic therapy for early stage breast cancer: A critical assessment of commercially available gene expression assays. J Surg Oncol (2017) 0.75
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med (2001) 44.67
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med (2001) 18.77
Mutations in the p53 gene occur in diverse human tumour types. Nature (1989) 13.62
Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med (1990) 11.57
Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science (1989) 11.53
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet (2005) 11.05
Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res (1997) 8.88
A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med (1983) 8.82
A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med (1990) 7.92
A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med (2001) 7.59
Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest (1981) 6.89
Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089. J Clin Oncol (2003) 5.71
p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res (1990) 5.70
The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress. Eur J Cancer (1994) 5.63
An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. JAMA (1993) 5.43
Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med (1997) 5.10
Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol (1996) 4.99
Lateral motion of fluorescently labeled acetylcholine receptors in membranes of developing muscle fibers. Proc Natl Acad Sci U S A (1976) 4.86
Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst (1998) 4.43
Exogenous expression of N-cadherin in breast cancer cells induces cell migration, invasion, and metastasis. J Cell Biol (2000) 4.33
The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod (1989) 4.13
Hospital and physician volume or specialization and outcomes in cancer treatment: importance in quality of cancer care. J Clin Oncol (2000) 4.01
Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med (1995) 3.83
Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A. Proc Natl Acad Sci U S A (2000) 3.61
erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst (1998) 3.56
Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med (1994) 3.54
The DCC protein and prognosis in colorectal cancer. N Engl J Med (1996) 3.51
Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res (1998) 3.39
2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol (2000) 3.38
Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med (1994) 3.29
2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol (2001) 3.25
Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. Nat Med (1996) 3.07
Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol (2001) 3.06
Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol (1997) 3.04
Surgery for recurrent colon cancer: strategies for identifying resectable recurrence and success rates after resection. Eastern Cooperative Oncology Group, the North Central Cancer Treatment Group, and the Southwest Oncology Group. Ann Intern Med (1998) 2.95
Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol (2006) 2.94
Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer. Nat Genet (1996) 2.93
Fluorescent tetramethyl rhodamine derivatives of alpha-bungarotoxin: preparation, separation, and characterization. Anal Biochem (1977) 2.92
Tissue distribution of a coelomic-epithelium-related antigen recognized by the monoclonal antibody OC125. Int J Gynecol Pathol (1983) 2.90
Immunohistochemical analysis of P-glycoprotein expression correlated with chemotherapy resistance in locally advanced breast cancer. Hum Pathol (1990) 2.88
The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. Nat Genet (1996) 2.82
BRCA-associated breast cancer in young women. J Clin Oncol (1998) 2.78
Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. J Clin Oncol (2000) 2.73
Influence of organ environment on the growth, selection, and metastasis of human colon carcinoma cells in nude mice. Cancer Res (1988) 2.67
Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers. Cancer (1995) 2.64
Impact of number of nodes retrieved on outcome in patients with rectal cancer. J Clin Oncol (2001) 2.54
Regulation of tumour necrosis factor-alpha processing by a metalloproteinase inhibitor. Nature (1994) 2.53
Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662. Clin Cancer Res (2001) 2.53
Symptom prevalence, characteristics and distress in a cancer population. Qual Life Res (1994) 2.46
Predictors of poor neurologic outcome after induced mild hypothermia following cardiac arrest. Neurology (2008) 2.44
Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer. Obstet Gynecol (1992) 2.43
Germline BRCA1 185delAG mutations in Jewish women with breast cancer. Lancet (1996) 2.40
In vivo selection of highly metastatic cells from surgical specimens of different primary human colon carcinomas implanted into nude mice. Cancer Res (1988) 2.36
Immunopathologic characterization of a monoclonal antibody that recognizes common surface antigens of human ovarian tumors of serous, endometrioid, and clear cell types. Am J Clin Pathol (1983) 2.33
Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat (2001) 2.26
Temperature and Excitability. J Physiol (1896) 2.21
Efficacy and cost-effectiveness of cancer treatment: rational allocation of resources based on decision analysis. J Natl Cancer Inst (1993) 2.21
Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study. Cancer Res (1998) 2.21
Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res (1991) 2.20
Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol (2000) 2.13
BCG and cancer (first of two parts). N Engl J Med (1974) 2.13
Surgical margin in hepatic resection for colorectal metastasis: a critical and improvable determinant of outcome. Ann Surg (1998) 2.10
Acquired cellular immunity: extracellular killing of Listeria monocytogenes by a product of immunologically activated macrophages. Cell Immunol (1974) 2.07
Evidence for secular trends in children's physical activity behaviour. Br J Sports Med (2005) 2.07
Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin. J Clin Invest (1980) 2.03
Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer. J Clin Oncol (1995) 2.02
A new venous prosthesis. Surgery (1972) 2.01
NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas. Proc Natl Acad Sci U S A (1999) 2.00
The clinical features of hepatic angiosarcoma: a report of four cases and a review of the English literature. Medicine (Baltimore) (1979) 1.99
Detecting gene copy number fluctuations in tumor cells by microarray analysis of genomic representations. Genome Res (2000) 1.99
The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGF-beta signaling. Oncogene (2009) 1.97
1st International consensus guidelines for advanced breast cancer (ABC 1). Breast (2012) 1.96
Differences in initial treatment patterns and outcomes of lung cancer in the elderly. Lung Cancer (1995) 1.95
An intensive sequenced adjuvant chemotherapy regimen for breast cancer. Cancer Invest (1993) 1.94
Neoadjuvant chemotherapy and liver transplantation for hepatocellular carcinoma: a pilot study in 20 patients. Gastroenterology (1993) 1.90
Antibiotic treatment of gastric lymphoma of mucosa-associated lymphoid tissue. An uncontrolled trial. Ann Intern Med (1999) 1.88
Cutaneous basophil hypersensitivity. 3. Participation of the basophil in hypersensitivity to antigen-antibody complexes, delayed hypersensitivity and contact allergy. Passive transfer. J Immunol (1971) 1.84
Factors influencing prognosis in node-negative breast carcinoma: analysis of 767 T1N0M0/T2N0M0 patients with long-term follow-up. J Clin Oncol (1993) 1.83
Surgical debulking and intraperitoneal chemotherapy for established peritoneal metastases from colon and appendix cancer. Ann Surg Oncol (2001) 1.83
Monoclonal antibody immunoradiometric assay for an antigenic determinant (CA 125) associated with human epithelial ovarian carcinomas. Cancer Res (1984) 1.83
Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. Semin Oncol (1999) 1.82
Tumor size, sensitivity to therapy, and design of treatment schedules. Cancer Treat Rep (1977) 1.82
Regulation of BAD phosphorylation at serine 112 by the Ras-mitogen-activated protein kinase pathway. Oncogene (1999) 1.81
Benzo[a]pyrene diol epoxide and bleomycin sensitivity and susceptibility to cancer of upper aerodigestive tract. J Natl Cancer Inst (1998) 1.81
An effect of pactamycin on the initiation of protein synthesis in reticulocytes. Biochem Biophys Res Commun (1970) 1.79
Genetic analysis of early- versus late-stage ovarian tumors. Cancer Res (2001) 1.77
Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer. J Natl Cancer Inst (1993) 1.77
Diffuse malignant mesothelioma. Prospective evaluation of 69 patients. Ann Intern Med (1982) 1.75
Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations. J Natl Cancer Inst (1999) 1.73
Communication skills training in oncology. Description and preliminary outcomes of workshops on breaking bad news and managing patient reactions to illness. Cancer (1999) 1.73
Pamidronate in prevention of bone complications in metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol (2000) 1.71